UniCredit Bonus Zert LLY 28.06.20.../ DE000HD3T9W4 /
20/05/2024 19:28:03 | Chg.0.000 | Bid20/05/2024 | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1,199.820EUR | 0.00% | - Bid Size: - |
- Ask Size: - |
ELI LILLY | - - | 28/06/2024 | Call |
GlobeNewswire
06:00
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Disease...
GlobeNewswire
30/05
Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
GlobeNewswire
30/05
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
24/05
Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District
GlobeNewswire
23/05
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire
16/05
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED ...
GlobeNewswire
16/05
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
GlobeNewswire
15/05
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
13/05
Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracel...
GlobeNewswire
09/05
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
09/05
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radioph...
GlobeNewswire
08/05
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
08/05
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire
08/05
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting...
GlobeNewswire
08/05
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results